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Abstract
Background: Multiple sclerosis (MS) is a chronic disease associated with several impacts; especially regarding patients’
health-related quality of life (HRQL). EuroQol 5 Dimensions questionnaire (EQ-5D) provides self-reported analysis of
HRQL and utility scores. Although the British algorithm to convert EQ-5D responses into utility is the most used in the
literature, national settings is more appropriate for health policy decision makers.
A Brazilian algorithm is available, but not used in MS patients yet. Primarily, this study aimed to address potential
differences in utility scores obtained through Brazilian and British value sets. Secondary objective was to determine the
role of disability, fatigue and patients socio-demographic and clinical characteristics relevant to MS on the utility scores
reported by Brazilian patients.
Methods: Cross-sectional study with MS patients treated in 8 Brazilian sites. Patients were interviewed about
socio-demographic and clinical characteristics, self-reported disability level, HRQL and impact of fatigue on daily living.
Disability level, HRQL and impact of fatigue were assessed using the Expanded Disability Status Scale (EDSS) and the
Brazilian versions of EQ-5D-3L and Modified Fatigue Impact Scale (MFIS-BR), respectively. Patients were classified in
subgroups according to EDSS (mild: 0–3; moderate: 4–6.5; severe: >7) and the self-perceived impact of fatigue
(absent: ≤38 points; low: 39–58; high: ≥59). EQ-5D-3 L data was converted into a utility index using an algorithm
developed by a Brazilian research group (QALY Brazil) and also the UK algorithm. Differences between utility scores
were analysed through Wilcoxon test.
Results: Two hundred and ten patients were included in the study. Utility index mean scores of 0.59 (SD = 0.22) and
0.56 (SD = 0.32)
for the Brazilian and UK algorithms were observed, respectively, without statistically significant difference for the
distribution of data (p = 0.586). However, when utility scores were lower than 0.5, Brazilian algorithm provided higher
estimates than UK with a better agreement between the scores found closer to 1. The same trend was observed when
data was stratified for EDSS and impact of fatigue, with statistically significant difference between scores in categories
of mild/severe disabilities and absent/high impact of fatigue.
Conclusions: Results suggest that Brazilian value set provided higher utility scores than the UK, particularly for
measures below 0.5.
* Correspondence: nilceia.lopes@novartis.com
2Novartis Biociências S.A., Avenida Prof. Vicente Rao, 90, São Paulo, SP, Brazil
Full list of author information is available at the end of the article
© 2015 Takemoto et al. Open Access This article is distributed under the terms of the Creative Commons Attribution
4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution,
and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in
this article, unless otherwise stated.
Takemoto et al. Health and Quality of Life Outcomes  (2015) 13:119 
DOI 10.1186/s12955-015-0318-1
Background
Multiple sclerosis (MS) is an inflammatory and demyelin-
ating disease of the central nervous system, which in most
cases involves motor, sensory, visual and cognitive alter-
ations, besides other clinical manifestations [1, 2]. It is
estimated that about 2.5 million people are living with the
disease worldwide. In Brazil, the estimated prevalence
ranges from 1.36 to 18.1/100,000 inhabitants, depending
on the characteristics of the studied population [1, 3].
The EQ-5D-3L is widely used to measure health-
related quality of life in MS. It allows both the descrip-
tive assessment of self-reported impairment in generic
dimensions of health and the estimation of utility scores,
being one of the most employed instrument in burden
of illness studies across several therapeutic areas [4–17].
Most of the studies using EQ-5D-3L to calculate utility
scores in MS patients use the algorithm developed for
the United Kingdom (UK), however a national value set
is more appropriate for health policy decision makers
[18, 19]. Recently, an algorithm to estimate Brazilian
preference weights for the 243 health states was described
by a Brazilian research group (QALY Brazil), which con-
ducted a household survey using the time trade-off tech-
nique to value EQ-5D-3L health states [20].
Thus, the primary aim of this study was to address
potential differences in utility scores obtained through
Brazilian and British value sets. Additionally, the se-
condary objective was to determine the role of disability,
fatigue and patients socio-demographic and clinical
characteristics relevant to MS natural history on the
utility scores reported by Brazilian patients.
Methods
Study design and patient assessment
This was a multicenter, cross-sectional study conducted
in eight centers in Southern and Southeastern Brazilian
regions, specialized in MS diagnosis and treatment. Pa-
tients were screened for eligibility and invited to partici-
pate consecutively, as they attended a routine visit at
study sites. If they agreed, they were asked to sign an in-
formed consent. Patients were deemed eligible if they
were at least 18 years old and if they had clinical diagno-
sis of MS according to the revised McDonald criteria
[21]. Patients were excluded if they had any physical or
mental condition that would impair their understanding
and ability to answer the study interview (particularly
the self-reported measures of HRQL and fatigue) and/or
they were already enrolled in a clinical trial at the time
of enrollment. This study was approved by the inde-
pendent Ethics Committees of each participating center.
During data collection, which occurred between
November/2011 and May/2012, patients answered a face-
to-face structured interview conducted by a clinical re-
search assistant during an outpatient routine visit, in order
to collect self-reported variables about socio-demographics
and clinical aspects, disability level, health-related quality
of life (HRQL) and impact of fatigue on daily living.
Disability level
Disability level was assessed by using the self-reported
Expanded Disability Status Scale (EDSS), a well estab-
lished method to assess MS-related disability in both
clinical trials and epidemiological studies [22]. Patients
were classified as having mild, moderate or severe
disability according to the following cutoffs: 0–3 (mild),
4–6.5 (moderate), and ≥7 (severe), as previously de-
scribed by other authors [4–6].
Health-related quality of life
EQ-5D-3L was used to assess health-related quality of
life. This instrument measures generic quality of life
through five different domains (mobility, self-care, usual
activities, pain/discomfort and anxiety/depression) in
which patients choose between 3 response levels (no
problem, some problem and serious problem) [23].
Utility
Data obtained from EQ-5D-3L was used to calculate an
index -utility score- which ranged from 0 to 1 (where
death = 0 and perfect health = 1). Utility measures are
based on patient judgment and indicate preferences for
health states, which means how well each state is pre-
ferred by individuals, groups or society [24].
Patient self-reported health status (consisting of the
answers to each EQ-5D-3L domain) was converted into
the EQ-5D-3L index using the UK value set, as described
by Dolan et al. (1997) and also using the algorithm de-
veloped by QALY Brazil Group in a Brazilian
population-based study [18–20].
Fatigue
Fatigue was assessed through MFIS-BR (Modified Fatigue
Impact Scale, Brazilian Portuguese version) which mea-
sures the impact of fatigue on quality of life through 21
questions on physical, cognitive and psychosocial domains
[25]. Impact of fatigue was considered as absent when
total score was ≤38 points, low when the score was be-
tween 39 and 58 points and high when ≥59 points. For the
purposes of this study, the impact of fatigue was used as
an independent variable potentially associated with the
utility scores estimates.
Statistical analysis
Shapiro-Wilk and Jarque-Bera tests were used to test nor-
mal distribution of data. All data were submitted to ex-
ploratory analysis to describe measures of central tendency
and dispersion for continuous variables, and frequency
measures for categorical variables. Non-parametric tests
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were employed in the analysis due to the non-normal dis-
tribution of data. For comparison of means among patient
subgroups (according to MS-relevant demographic and
clinical characteristics), t-test and Kruskal-Wallis were used.
Wilcoxon for paired samples was used to test the difference
between UK and Brazilian scores. Intra-class correlation co-
efficient (ICC) was used to assess the reliability between
measures of utility. Bland–Altman plot were also con-
structed to further assess agreement between BR and UK
values, as previously described [26]. Analyses were per-
formed using the statistical software STATA (version
MP12; StataCorp. 2011; College Station, TX). The p-value
≤0.05 was assumed for statistical significance.
Ethical approval and consent
All procedures performed in studies involving human par-
ticipants were in accordance with the ethical standards of
the institutional and/or national research committee and
with the 1964 Helsinki declaration and its later amend-
ments or comparable ethical standards. Informed consent
was obtained from all individual participants included in
the study. The study protocol was submitted and approved
by each Institutional Review Board of the eight participating
sites: Centro de Pesquisa Clínica do HCPA (Protocol num-
ber: 110267); Hospital de Clínicas da UNICAMP (Protocol
number: 433/2011); Santa Casa de São Paulo (Protocol
number: 173/11); Hospital das Clínicas da Faculdade de
Medicina da USP (Protocol number: 0571/11); Centro de
Pesquisas da Neurologia da UNIFESP (Protocol number:
0769/11); Universidade Metropolitana de Santos –
UNIMES (Protocol number: 018/2011); Centro de Pesqui-
sas Clínicas do HSL – PUCRS (Protocol number: 12/
05750); and Clínica Neurológica e Neurocirúrgica de Join-
ville Ltda (Protocol number: 12004).
Results
Patient demographic and disease characteristics
Two hundred and ten consecutive patients met eligibility
criteria and were included in the study. Patients’ demo-
graphic and disease characteristics are shown in Table 1.
Utility
Mean utility scores of 0.59 (SD = 0.22) and 0.56 (SD = 0.32)
for the Brazilian and UK algorithms were observed for the
total sample, with no statistically significant difference
among the distribution of data (p = 0.586, Wilcoxon test
for paired samples). Although statistical significance was
not reached, the Bland-Altman plot depicted in Fig. 1
demonstrates that when utilities scores are lower than 0.5,
Brazilian algorithm provides higher estimates than UK,
and that a better agreement between estimated utility
scores is found closer to 1. A good correlation among the
estimates was found (ICC = 0.92), despite differences in
Table 1 Clinical and demographic characteristics of the













Never been to school -
Elementary school (complete/incomplete) 35 (16)
High school (complete/incomplete) 100 (48)
Graduation (complete/incomplete) 61 (29)
Post-Graduation (complete/incomplete) 13 (6)
No information 1 (1)
Occupation
Employed 68 (33)
Not employeda 140 (67)
MS type
Relapsing-remitting 166 (79)




Min-Max 1 – 30
Disability (EDSS) 208 (99)
0 - 3 84 (40)
4 - 6.5 91 (44)
7 - 9 33 (16)









Min-Max 0 – 5
aNot employed includes students, housewives, retirees and unemployed
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distribution of data, which may explain the lack of statis-
tical significance in the comparison analyses.
Utility scores and patients characteristics
Comparison of utility scores derived by Brazilian and
UK algorithms according to socio-demographic and
clinical characteristics is shown in Table 2. Subgroups
segmented by age, educational level, type of MS and
duration of the disease demonstrated statistically sig-
nificant differences when considering both Brazilian and
UK algorithms. In both algorithms (Brazilian and UK),
the utility score increased in accordance with the in-
crease in educational level (p < 0.001) and the disease
duration (p = 0.002). When age groups were compared,
also in both algorithms, those with age between 31 and
60 years old had lower utility scores (p = 0.004). Higher
utility scores were observed for relapsing-remitting MS
patients, when compared to those with secondary pro-
gressive MS with both algorithms (p < 0.001).
Utility scores and EDSS
Utility measures were also assessed by disability levels
(EDSS) and the distribution of data is presented in box
plots shown in Fig. 2. It was observed that the utility score
decreased in accordance with the increase of disability
level (p < 0.001 for both Brazilian and UK values). Patients
with mild symptoms of disability (EDSS: 0–3) had a mean
utility score of 0.738 (SD = 0.17) and 0.731 (SD = 0.21) for
Brazilian and UK algorithms, respectively. When the
Wilcoxon analysis was performed, a significant difference
among the distribution of mean scores was observed (p =
0.007). The existence of outlier values in the UK analyses
shown in Fig. 2 may justify the difference found although the
mean values were very similar. Data shown in the Bland-
Altman plot corroborates these findings, describing an agree-
ment for measures above 0.5 and higher values for Brazilian
measure when the score is below this cut-off (Fig. 3).
When the group with severe disabilities (EDSS: 7–9) was
assessed, mean utility values observed were 0.387 (SD =
0.22) with the Brazilian algorithm and 0.299 (SD = 0.34)
with the UK algorithm. Among these patients, a significant
difference between the distribution of measures was also
observed (p = 0.013, Wilcoxon test) – the score calculated
by the UK value set showed a greater range than the Brazil-
ian estimate (Fig. 2). Following the same trend described by
patients with mild disability, an agreement is observed for
higher utility values and the Brazilian measure tended to be
higher when the score is below 0.4 (Fig. 3).
The only group in which a statistical significant dif-
ference among the utility measures was not observed
was for patients with moderate disability (EDSS: 4–6.5)
(p = 0.917), with mean scores of 0.533 (SD = 0.18) and
0.492 (SD = 0.30) for Brazilian and UK algorithms, re-
spectively (Fig. 2). Despite the absence of a significant
difference, the same pattern was observed in the Bland-
Altman plot for this group, where a disagreement is
found when the score is below 0.4 (Fig. 3).
Utility scores and fatigue
Utility measures were then stratified by fatigue levels
(Fig. 4). There were significant differences between the















0 1−0.2 0.2 0.4 0.6 0.8
Mean
Fig. 1 Bland–Altman plot - comparison of utility scores derived by Brazilian and UK algorithms. Difference between the two utility scores (y-axis)
is plotted against their mean (x-axis)
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between the impact of fatigue and the utility score (p <
0.001 for both Brazilian and UK measures).
Patients with no fatigue impact (MFIS-BR: <38) had a
mean utility score of 0.719 (SD = 0.18) and 0.718
(SD = 0.24) using Brazilian and UK algorithms,
respectively (p = 0.001, Wilcoxon test for differences in
data distribution). Wilcoxon analysis evaluates the distri-
bution of data rather than the difference of means; there-
fore, the outlier values observed in UK measure may
explain the difference found, even with very similar mean
values (Fig. 4). The same trend was observed in Bland-
Altman plot, where a difference between utility scores and
fatigue impact was observed for a utility score below 0.5
(Fig. 5).
Among patients with high fatigue impact (MFIS-
BR: ≥59), mean utility observed was 0.448 (SD = 0.20)
and 0.368 (SD = 0.31) for Brazilian and UK algorithms,
respectively. Comparing the distribution of the scores,
significant differences were found (p = 0.027) and the
measure provided by the UK algorithm had a greater
range (Fig. 4). Similar to the pattern observed above, an
agreement is apparent only for higher utility values
(above 0.4) (Fig. 3).
Patients with low impact of fatigue (MFIS-BR: 39–58)
had a mean utility score of 0.488 (SD = 0.20) and 0.424
(SD = 0.31) for Brazilian and UK algorithm, respectively.
No differences in distribution of data was observed in
this group (p = 0.233), however the same pattern of a
higher difference among the two estimates was observed
when the utility value is lower than 0.5 (Figs. 4 and 5).
Discussion
This study aimed to address potential differences in util-
ities derived from the well-established UK value set, as
described by Dolan et al. [18], and the newly published
Brazilian value set, obtained through a household-based
study conducted with 9,148 subjects in Minas Gerais
state and Rio de Janeiro, Porto Alegre and Recife cities
[27]. Patients’ health status was assessed by using EQ-
5D-3L and then the EQ-5D-3L data were converted into
a utility index using Brazilian and UK value sets. To our
knowledge, this is the first study that used the algorithm
proposed by QALY Brazil group in a Brazilian sample of
patients with MS and also compared the findings with
the most used method in literature.
Patients participating in the study were mainly female
with a mean age of 40.7 years old. Demographic character-
istics are comparable with those previously described for
Brazilian MS patients and in studies that assessed quality
of life in MS worldwide [4–16, 28–31]. Most of the pa-
tients had relapsing-remitting MS, moderate disability and
a mean utility score of 0.59 (SD = 0.22) and 0.56 (SD =
0.32) for the Brazilian and UK algorithms, respectively.
Other studies with similar clinical characteristics de-
scribed utility scores ranging from 0.491 to 0.698 in MS
patients [11, 13, 30].
Considering the total sample, statistical significant differ-
ences among the Brazilian (0.59 [SD = 0.22]) and UK (0.56
[SD = 0.32]) algorithms were not observed (p = 0.586,
Table 2 Utility measures according to socio-demographic and
clinical characteristics
Dimension BR utility mean (SD)
p-value
UK utility mean (SD)
p-value
Age
18-30 0.675 (0.20) 0.679 (0.24)
31-60 0.564 (0.23) 0.509 (0.34)
61+ 0.599 (0.22) 0.633 (0.32)
0.004 0.004
Gender
Male 0.561 (0.21) 0.539 (0.29)
Female 0.607 (0.23) 0.566 (0.33)
0.126 0.320
Living
Alone 0.524 (0.15) 0.525 (0.26)
Family 0.597 (0.23) 0.558 (0.32)
0.152 0.364
Educational level
Until elementary school 0.481 (0.23) 0.410 (0.35)
Between elementary
and high school
0.582 (0.22) 0.531 (0.32)
Graduation and
Post-graduation
0.663 (0.19) 0.667 (0.26)
<0.001 <0.001
Occupation
Not employed 0.536 (0.22) 0.492 (0.33)
Employed 0.709 (0.18) 0.693 (0.24)
<0.001 <0.001
MS Type
Relapsing-remitting 0.635 (0.21) 0.606 (0.30)
Secondary progressive 0.440 (0.21) 0.380 (0.33)
<0.001 <0.001
Recurrence
Yes 0.579 (0.21) 0.535 (0.31)
No 0.606 (0.23) 0.576 (0.33)
0.249 0.204
Diagnosis time
<10 years 0.534 (0.24) 0.463 (0.35)
≥10 years 0.635 (0.20) 0.622 (0.27)
0.002 0.002
Total
Mean(SD) 0.593 (0.223) 0.557 (0.319)
Median(IQR) 0.625 (0.472 - 0.742) 0.656 (0.414 - 0.779)
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Wilcoxon test for paired samples). This finding is different
compared to results from studies comparing value sets for
Argentina [32], Chile [32], Denmark [33], Japan [26],
United States [26, 33, 34], UK [26, 32–35] and Spain [35].
However, similar to the results described here, all studies so
far have shown lower values when UK algorithm was used
for analysis (as compared to the local value set). Statistical
tests comparing distribution of data showed that most dif-
ferences between algorithms can be observed at lower util-
ity scores as shown in this study and also in previous
studies comparing local value sets with the one from UK
[26, 32–34].
Differences among utility scores have been attributed
in the literature to two main factors: methods used to
collect and to rate each of the EQ-5D-3L health status;
and cultural characteristics of the sample used [18, 27].
The most important differences among the methods
used for UK and the QALY Brazil group were the
number of health states used to estimate the value sets
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Fig. 2 Brazilian and UK utility scores distribution stratified by EDSS levels. Medians of utility scores according to the three groups of disabilities














































Fig. 3 Bland-Altman plot: Brazilian and UK utility scores stratified by EDSS levels. Difference between the two utility scores (y-axis) is plotted
against their mean (x-axis), according to the three groups of disabilities (mild, moderate and severe) in MS patients
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proposed by Kind (2009). However, the method to value
each of the health states was the same (the time-trade-off
technique) [36]. The EQ-5D-3L questionnaire provides
243 possible health states and valuation studies employ a
subset of those health states and then apply statistical
modelling to derive the remaining states. The Brazilian
valuation study used 99 health states while the UK used
42 health states [27, 37]. The use of greater than 42 health
states in the rating process was described only by the
Brazilian and South Korean studies and researchers have
discussed that it may provide the most simple and robust
models [38–47]. The protocol proposed by Kind [36]
brings three main updates to the EQ-5D-3L health states
valuation process, which consists in shuffling cards
describing the states before patients classify each one, the









Fatigue impact (MFIS Scale)
Brazilian Utility Score UK Utility Score
Fig. 4 Brazilian and UK utility scores distribution stratified by fatigue levels. Medians of utility scores according to the three levels of fatigue


















































Fig. 5 Bland-Altman plot: Brazilian and UK utility scores stratified by fatigue levels. Difference between the two utility scores (y-axis) is plotted
against their mean (x-axis), according to the three levels of fatigue impact (absent, high and low) in MS patients
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procedure of giving all cards at the same time to subjects.
The rating of value sets is based on the time trade off
method, where patients determine how long they could
live under the proposed health state and whether it seems
similar to death or perfect health. Cultural characteristics
may influence the final model of the developed algorithm.
To investigate potential cultural factors that may influ-
ence the difference in utility scores is not the scope of
the present analysis, but previous authors have sug-
gested that this may be explained by country-specific
differences in the way people perceive and value health
conditions [26, 32, 33, 35].
This study also assessed the role of disability (according
to EDSS disability level), fatigue (using MFIS-BR) and pa-
tient’s socio-demographic and clinical characteristics rele-
vant to MS natural history on the utility scores reported
by Brazilian patients. In terms of self-reported EDSS sub-
groups (0–3, 4–6.5, 7–9), the increase in self-perceived
disability level was accompanied by a decrease in the util-
ity index for both Brazilian and UK value set, which are
similar with findings from previous studies [4–16, 30, 31,
48–50]. Regarding the assessment of self-reported impact
of fatigue, the results observed in our study using the
MFIS-BR (59 %) differed from data previously described
for Brazil. Nogueira et al. (2009) found higher frequencies
of self-reported impact of fatigue (69 %, using the MFIS-
BR) and Mendes et al. (2000) using the Fatigue Severity
Scale reported a frequency of 67.4 % [51, 52]. Despite this
fact, an association between utility and fatigue was also
observed, as previously described by other authors who
examined the same association using different quality of
life measures [52]. Other variables such as age, educa-
tional level, employment status, MS type and disease
duration were also significantly associated with utility
scores. Those between-groups differences were consistent
for both Brazilian and UK values.
It is important to consider that this study presented
some limitations. Although this was a multicenter study,
all study sites were from South and Southeastern Brazil-
ian regions, which are different from other regions in
terms of socio-demographic characteristics; and in terms
of coverage and access to health care services. Thus,
findings may not be representative from the entire
country. Another limitation of this study was the self-
reported approach to the data collection process, which
can lead to memory bias – but is the most adopted
approach in patient-reported outcomes studies due to
the nature of targeted data. Regarding the variables
assessed in this analysis, clinical characteristics (type of
MS, recurrence and disease duration) are probably the
most prone to bias if self-reported. Thus, the association
between those variables and utility scores in MS can be
further addressed in studies using other source of data
or even combining different ones.
In spite of that, considering the widespread use of EQ-
5D-3L in the decision process for evaluating new thera-
pies in health systems worldwide, through cost-utility
analysis, these findings could markedly be relevant for
policy makers during the health technology assessment
of MS treatments that can affect patient’s quality of life
by slowing disability worsening and postponing pro-
gression to secondary progressive MS, reducing fatigue
symptoms, and favoring work productivity [53].
Conclusions
The results suggest that the Brazilian value set provides
higher EQ-5D-3L index scores than the UK, particularly
for utility scores below 0.5 (the lower the utility, the
higher the discrepancy among valuation methods). How-
ever, the impact of the differences in these EQ-5D-3L
index scores on the outcome of cost-utility analysis
needs to be further addressed.
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